Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.70 CAD
Change Today 0.00 / 0.00%
Volume 0.0
IGX On Other Exchanges
Symbol
Exchange
OTC US
Venture
As of 3:45 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

intelgenx technologies corp (IGX) Snapshot

Open
C$0.70
Previous Close
C$0.70
Day High
C$0.70
Day Low
C$0.70
52 Week High
03/31/15 - C$1.15
52 Week Low
11/5/14 - C$0.39
Market Cap
44.5M
Average Volume 10 Days
4.4K
EPS TTM
--
Shares Outstanding
63.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTELGENX TECHNOLOGIES CORP (IGX)

Related News

No related news articles were found.

intelgenx technologies corp (IGX) Related Businessweek News

No Related Businessweek News Found

intelgenx technologies corp (IGX) Details

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. Its product portfolio comprises INT0001/2004 for coronary heart failure and hypertension; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for the treatment of migraine; INT0010/2006 for cancer pain; INT0024/2010 for idiopathic pulmonary fibrosis; INT0027/2011 for opioid dependence; INT0030/2011 for animal health; and INT0036/2012 for central nervous system disorders, as well as INT0037/2013, INT0039/2013, and INT0040/2013. The company develops its products based on three delivery platform technologies, which consist of the Multilayer Tablet technology that allows for the development of oral controlled-release products; the Oral Film technology, which allows for the delivery of pharmaceuticals to the oral cavity; and the Mucoadhesive Tablet technology for the controlled release of active substances to the oral mucosa. It also provides product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets. The company has a strategic alliance with LTS Lohmann Therapie-Systeme AG to manufacture pharmaceutical products using VersaFilm drug delivery technology; and a strategic manufacturing partnership with Pillar5 Pharma Inc. It also has a co-development and commercialization agreement with RedHill Biopharma Ltd. for the co-development and commercialization of INT0008/2007. IntelGenx Technologies Corp. was founded in 2003 and is based in Ville Saint Laurent, Canada.

12 Employees
Last Reported Date: 03/31/15
Founded in 2003

intelgenx technologies corp (IGX) Top Compensated Officers

Founder, Chairman of the Board, Chief Executi...
Total Annual Compensation: $142.1K
Compensation as of Fiscal Year 2014.

intelgenx technologies corp (IGX) Key Developments

IntelGenx Technologies Corp. Appoints Andr Godin, CPA, CA as Executive Vice-President and Chief Financial Officer

IntelGenx Technologies Corp. announced that it entered into an employment agreement with Andr Godin, CPA, CA, appointing him Executive Vice-President and Chief Financial Officer effective August 24, 2015. The Board appointed Mr. Godin as Chief Financial Officer effective July 20, 2015. Mr. Godin has more than 25 years experience in the Biotech/Pharma industry. Most recently, he served as Interim CEO and CFO of Neptune Technologies and Bioresources Inc. and both of its subsidiaries Acasti and NeuroBioPharm. He started with Neptune in 2003 as Vice President, Administration and Finance and was named its Chief Financial Officer in 2008.

IntelGenx Technologies Corp. Announces Financial Results for Six Months Ended June 30, 2015

IntelGenx Technologies Corp. announced financial results for six months ended June 30, 2015. Revenue for the six months ended June 30, 2015 was $1,210,000, up threefold over the $382,000 realized in the first six months of 2014. The company generated an operating loss of $246,000 during the first six months of 2015, compared with an operating loss of $1,068,000 during the first six months of 2014. The net loss was $328,000 for the first six months of 2015, down from $1,056,000 during the first six months of 2014.

IntelGenx Technologies Corp. Appoints Clemens Mayr as New Director

IntelGenx Technologies Corp. announced that Mr. Clemens Mayr has accepted his appointment to serve on the company's board of directors. Since 2006, Clemens Mayr is a partner of McCarthy Ttrault LLP. His practice focusses on M&A and capital markets, both domestic and cross-border.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IGX:CN C$0.70 CAD 0.00

IGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $6.16 USD -0.28
View Industry Companies
 

Industry Analysis

IGX

Industry Average

Valuation IGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.6x
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELGENX TECHNOLOGIES CORP, please visit www.intelgenx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.